Reirradiation in Head and Neck Recurrent or Second Primary Tumor: Efficacy,Safety,and Prognostic Factors

Abstract

Aims and background

We investigated efficacy, safety, and prognostic factors of reirradiation in patients with recurrent or second primary head and neck cancer.

Methods

Records of 75 consecutive patients treated with reirradiation between August 2005 and December 2013 were reviewed.

Results

Median overall survival (OS) and cancer-specific survival (CSS) were 29.5 and 33.6 months. Median local control (LC) and progression-free survival (PFS) were 21.7 and 16.2 months. Univariate analysis showed that patients younger than 70 years, with a Karnofsky Performance Status (KPS) >90 or with 2 or less comorbidities at time of reirradiation, have a better OS; KPS >90 and biological equivalent dose (BED) >72 Gy positively influenced the PFS. At multivariate analysis, KPS at reirradiation was an independent predictive factor for OS, while BED was an independent predictive factor for CSS and OS. At univariate analysis, patients with planning target volume (PTV) >221 mL had worse LC and PFS rates, with results confirmed at multivariate analysis. The rate of fatal treatment-related adverse events was 6.7% (3 carotid blowout, 1 soft tissue necrosis, and 1 thromboembolic event).

Conclusions

This study confirms the role and outcomes of reirradiation. A careful selection of patients could minimize acute and late side effects and influence survival: elderly patients, with significant medical comorbidities or poor KPS, are worse candidate for reirradiation. Total dose delivered with reirradiation and PTV appear to be other potential prognostic factors. Further studies of dose escalation are needed to establish the total dose that could achieve better LC rates with a safer toxicity profile.

Keywords

Head and neck cancer Prognostic factors Reirradiation

Get full access to this article

View all access options for this article.

References

Pignon

J.P.

, Bourhis

, Domenge

, Designé

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355(9208): 949–955.

Eskander

, Merdad

, Irish

J.C.

Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. 2014; 36(12): 1820–1834.

Garden

A.S.

, Kies

M.S.

, Morrison

W.H.

Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013; 8(1): 21.

Bernier

, Domenge

, Ozsahin

; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19): 1945–1952.

Jones

A.S.

, Bin Hanafi

, Nadapalan

, Roland

N.J.

, Kinsella

, Helliwell

T.R.

Do positive resection margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer. 1996; 74(1): 128–132.

Ridge

J.A.

Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol. 1993; 20(5): 419–429.

Goodwin

W.J.

Jr.

Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?

Laryngoscope. 2000; 110(3 Pt 2)(Suppl 93): 1–18.

Wong

L.Y.

, Wei

W.I.

, Lam

L.K.

, Yuen

A.P.

Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003; 25(11): 953–959.

Agra

I.M.

, Carvalho

A.L.

, Ulbrich

F.S.

Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006; 28(2): 107–113.

10.

Forastiere

A.A.

, Metch

, Schuller

D.E.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10(8): 1245–1251.

11.

Gibson

M.K.

, Li

, Murphy

; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23(15): 3562–3567.

12.

Lartigau

E.F.

, Tresch

, Thariat

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol. 2013; 109(2): 281–285.

13.

Balermpas

, Keller

, Hambek

Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys. 2012; 83(3): e377–e383.

14.

Chen

A.M.

, Farwell

D.G.

, Luu

, Cheng

, Donald

P.J.

, Purdy

J.A.

Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; 80(3): 669–676.

15.

Comet

, Kramar

, Faivre-Pierret

Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012; 84(1): 203–209.

16.

Langer

C.J.

, Harris

, Horwitz

E.M.

Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25(30): 4800–4805.

17.

Langendijk

J.A.

, Kasperts

, Leemans

C.R.

, Doornaert

, Slotman

B.J.

A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006; 78(3): 306–312.

18.

Spencer

S.A.

, Harris

, Wheeler

R.H.

Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 30(3): 281–288.

19.

Duprez

, Madani

, Bonte

Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol. 2009; 93(3): 563–569.

20.

Salama

J.K.

, Vokes

E.E.

, Chmura

S.J.

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006; 64(2): 382–391.

21.

De Crevoisier

, Bourhis

, Domenge

Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998; 16(11): 3556–3562.

22.

National Cancer Institute.

Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 2009 May. Available at: http://evs.nci.nih.gov/. Accessed June 10, 2015.

23.

Karnofsky Performance Status Scale definitions rating (%) criteria. Available at: http://www.npcrc.org/files/news/karnof-sky_performance_scale.pdf. Accessed June 6, 2015.

24.

Charlson

M.E.

, Pompei

, Ales

K.L.

, MacKenzie

C.R.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373–383.

25.

Singh

, Bhaya

, Stern

Validation of the Charlson Comorbidity Index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997; 107(11 Pt 1): 1469–1475.

26.

Tanvetyanon

, Padhya

, McCaffrey

Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009; 27(12): 1983–1991.

27.

Heron

D.E.

, Ferris

R.L.

, Karamouzis

Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009; 75(5): 1493–1500.

28.

Rwigema

J.C.

, Heron

D.E.

, Ferris

R.L.

The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2011; 34(4): 372–379.

29.

Ozyigit

, Cengiz

, Yazici

A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4): e263–e268.

30.

Chen

A.M.

, Phillips

T.L.

, Lee

N.Y.

Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?

Int J Radiat Oncol Biol Phys. 2011; 81(5): 1211–1219.

31.

Cacicedo

, Navarro

, Alongi

The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. Cancer Treat Rev. 2014; 40(1): 178–189.

32.

Vargo

J.A.

, Heron

D.E.

, Ferris

R.L.

Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. Head Neck. 2014; 36(9): 1349–1355.

33.

McDonald

M.W.

, Moore

M.G.

, Johnstone

P.A.

Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys. 2012; 82(3): 1083–1089.

34.

Yamazaki

, Ogita

, Kodani

Frequency, outcome and prognostic factors of carotid blowout syndrome after hypofractionated re-irradiation of head and neck cancer using CyberKnife: a multi-institutional study. Radiother Oncol. 2013; 107(3): 305–309.

35.

Yazici

, Sanli

T.Y.

, Cengiz

A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reir-radiaton for recurrent head and neck cancers. Radiat Oncol. 2013; 8(1): 242.